These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7620177)

  • 1. With first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially?
    Korbling M; Przepiorka D; Gajewski J; Champlin RE; Chan KW
    Blood; 1995 Aug; 86(3):1235. PubMed ID: 7620177
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of apheresis content of progenitor cell collections from normal donors to whom granulocyte-colony-stimulating factor is administered.
    Weinthal JA; Nemunaitis JJ; Aston S; Magsamen MJ; Rosenfeld CS
    Transfusion; 1996; 36(11-12):943-7. PubMed ID: 8937400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic transplant potential of unrelated cord blood: critical issues.
    Kögler G; Callejas J; Hakenberg P; Enczmann J; Adams O; Däubener W; Krempe C; Göbel U; Somville T; Wernet P
    J Hematother; 1996 Apr; 5(2):105-16. PubMed ID: 8723785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors.
    Crisalli LM; Hinkle JT; Walling CC; Sell M; Frey NV; Hexner EO; Loren AW; Luger SM; Stadtmauer EA; Porter DL; Reshef R
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1203-1208. PubMed ID: 29408506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of number of apheresis procedures necessary in healthy donors to attain minimally required peripheral blood CD34+ cells.
    Namba N; Matsuo K; Kubonishi S; Kikuchi T; Maeda Y; Niiya M; Shinagawa K; Koide N; Ikeda K; Tanimoto M
    Transfusion; 2009 Nov; 49(11):2384-9. PubMed ID: 19624602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the role of apheresis technology in stem cell transplantation?
    Kiki I
    Transfus Apher Sci; 2017 Dec; 56(6):788-794. PubMed ID: 29162394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Allogeneic hematopoietic stem cell transplantations].
    Michallet M
    Transfus Clin Biol; 2011 Apr; 18(2):235-45. PubMed ID: 21466967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
    Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
    Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apheresis and transplant of hematopoietic progenitor cells (HPC) from allogeneic donors of age above 60 years.
    Janssen WE; Rahn D; Hackett M; Coyle D; Tomblyn M; Smilee RC; Anasetti C; Fernandez HF
    Bone Marrow Transplant; 2012 Dec; 47(12):1520-5. PubMed ID: 22562079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes from unrelated donor hematopoietic stem cell transplantation.
    Perez LE
    Cancer Control; 2011 Oct; 18(4):216-21. PubMed ID: 21976240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation.
    Díaz MA; Sevilla J; de la Rubia J; Verdeguer A; Espigado I; Vicent MG; Pascual MJ; Zamora C; Arrieta R; Serrano D; del Cañizo C; Arbona C; de Arriba F; Bargay J; Brunet S; Sanz MA
    Haematologica; 2003 Aug; 88(8):919-22. PubMed ID: 12935980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.
    Engelhardt M; Bertz H; Wäsch R; Finke J
    Ann Hematol; 2001 Apr; 80(4):201-8. PubMed ID: 11401085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors.
    Körbling M; Chan KW; Anderlini P; Seong D; Durett A; Langlinais A; Przepiorka D; Gajewski J; Miller P; Sundberg J; Alilaen P; Bojko P; Mirza N; Claxton D; van Besien K; Khouri I; Andersson B; Mehra R; Champlin R
    Bone Marrow Transplant; 1996 Nov; 18(5):885-90. PubMed ID: 8932841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections.
    Anderlini P; Lauppe J; Przepiorka D; Seong D; Champlin R; Körbling M
    Br J Haematol; 1997 Feb; 96(2):415-7. PubMed ID: 9029035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors.
    Martínez C; Urbano-Ispizua A; Marín P; Merino A; Rovira M; Carreras E; Montserrat E
    Bone Marrow Transplant; 1999 Dec; 24(12):1273-8. PubMed ID: 10627634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring blood for CD34+ cells to determine timing of Hematopoietic Progenitor Cells Apheresis.
    Vaughn ML; Waller EK
    Methods Mol Biol; 2012; 904():79-83. PubMed ID: 22890923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors.
    Ottinger HD; Ferencik S; Beelen DW; Lindemann M; Peceny R; Elmaagacli AH; Husing J; Grosse-Wilde H
    Blood; 2003 Aug; 102(3):1131-7. PubMed ID: 12689945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
    Nakane T; Nakamae H; Yamaguchi T; Kurosawa S; Okamura A; Hidaka M; Fuji S; Kohno A; Saito T; Aoyama Y; Hatanaka K; Katayama Y; Yakushijin K; Matsui T; Yamamori M; Takami A; Hino M; Fukuda T
    Int J Hematol; 2017 Apr; 105(4):485-496. PubMed ID: 27943166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.